Can a common cholesterol drug help manage a rare liver disease?

NCT ID NCT07104201

Ongoing Disease control Sponsor: Xijing Hospital of Digestive Diseases Source: ClinicalTrials.gov ↗

First seen Jul 29, 2026 · Last updated Jul 30, 2026 · Updated 1 time

Summary

This trial is testing the long-term safety of fenofibrate, a drug usually used for high cholesterol, in people with primary biliary cholangitis (PBC), a rare liver disease. The study involves 15 adults who have already completed a previous fenofibrate trial for PBC. Researchers are monitoring side effects and changes in liver function to see if the drug remains safe over an extended period.

What this could mean

Our plain-language read of the trial. This is informational only — not medical advice or a prediction.

Active substance: a drug called fenofibrate, typically used to lower fats in the blood
What this could lead to: If fenofibrate proves safe over the long term, it could become an additional treatment option for managing PBC.
What could go wrong: This is a very early, small study with only 15 participants, so results may not apply to everyone. Side effects from fenofibrate are possible.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for PRIMARY BILIARY CHOLANGITIS (PBC) are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

primary biliary cholangitis

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

PRIMARY BILIARY CHOLANGITIS (PBC)

Contacts and locations

Locations

Xijing Hospital

Xi'an, Shaanxi, 710032, China

More trials for these conditions

Other studies related to the condition(s) this trial covers.